Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Boehringer Ingelheim
McKesson
McKinsey
Mallinckrodt

Last Updated: August 17, 2022

VIZAMYL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Vizamyl, and what generic alternatives are available?

Vizamyl is a drug marketed by Ge Healthcare and is included in one NDA. There are five patents protecting this drug.

This drug has eighty-three patent family members in twenty-four countries.

The generic ingredient in VIZAMYL is flutemetamol f-18. One supplier is listed for this compound. Additional details are available on the flutemetamol f-18 profile page.

DrugPatentWatch® Generic Entry Outlook for Vizamyl

Vizamyl was eligible for patent challenges on October 25, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 16, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for VIZAMYL
International Patents:83
US Patents:5
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 3
Clinical Trials: 6
Patent Applications: 144
Drug Prices: Drug price information for VIZAMYL
What excipients (inactive ingredients) are in VIZAMYL?VIZAMYL excipients list
DailyMed Link:VIZAMYL at DailyMed
Drug patent expirations by year for VIZAMYL
Drug Prices for VIZAMYL

See drug prices for VIZAMYL

DrugPatentWatch® Estimated Generic Entry Opportunity Date for VIZAMYL
Generic Entry Date for VIZAMYL*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VIZAMYL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Yale UniversityPhase 1
University of UtahPhase 2
University Hospital, ToulouseEarly Phase 1

See all VIZAMYL clinical trials

Pharmacology for VIZAMYL

US Patents and Regulatory Information for VIZAMYL

VIZAMYL is protected by five US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VIZAMYL is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VIZAMYL

Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: DIAGNOSTIC RADIOIMAGING

Thioflavin derivatives for use in the antemortem diagnosis of Alzheimers disease and in vivo imaging and prevention of amyloid deposition
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: DIAGNOSTIC RADIOIMAGING

Benzothiazole derivative compounds, compositions and uses
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Benzothiazole derivative compounds, compositions and uses
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: DIAGNOSTIC RADIOIMAGING

Radiopharmaceutical composition
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 DISCN Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-002 Oct 25, 2013 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for VIZAMYL

When does loss-of-exclusivity occur for VIZAMYL?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 08292201
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 0815129
Estimated Expiration: See Plans and Pricing

Canada

Patent: 94084
Estimated Expiration: See Plans and Pricing

China

Patent: 1790387
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 82988
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 82988
Estimated Expiration: See Plans and Pricing

Hong Kong

Patent: 46710
Estimated Expiration: See Plans and Pricing

Hungary

Patent: 500007
Estimated Expiration: See Plans and Pricing

Israel

Patent: 3316
Estimated Expiration: See Plans and Pricing

Japan

Patent: 67708
Estimated Expiration: See Plans and Pricing

Patent: 10536931
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 10002196
Estimated Expiration: See Plans and Pricing

New Zealand

Patent: 3616
Estimated Expiration: See Plans and Pricing

Norway

Patent: 15006
Estimated Expiration: See Plans and Pricing

Poland

Patent: 82988
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 82988
Estimated Expiration: See Plans and Pricing

Russian Federation

Patent: 75267
Estimated Expiration: See Plans and Pricing

Patent: 10101935
Estimated Expiration: See Plans and Pricing

South Africa

Patent: 1000718
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 1571572
Estimated Expiration: See Plans and Pricing

Patent: 100055440
Estimated Expiration: See Plans and Pricing

Spain

Patent: 64715
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VIZAMYL around the world.

Country Patent Number Title Estimated Expiration
Australia 2011200667 Benzothiazole derivative compounds, compositions and uses See Plans and Pricing
World Intellectual Property Organization (WIPO) 2004083195 See Plans and Pricing
Slovenia 1334091 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for VIZAMYL

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1611115 92634 Luxembourg See Plans and Pricing PRODUCT NAME: FLUTEMETAMOL (18F) ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (VIZAMYL). FIRST REGISTRATION: 20140826
1334091 PA2015001,C1334091 Lithuania See Plans and Pricing PRODUCT NAME: FLUTEMETAMOLIS (18F); REGISTRATION NO/DATE: EU/1/14/941 20140822
2182988 C300723 Netherlands See Plans and Pricing PRODUCT NAME: FLUTEMETAMOL (18 F); REGISTRATION NO/DATE: EU/1/14/941 20140822
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Johnson and Johnson
AstraZeneca
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.